[Targeted therapy in lung cancer: molecular testing using cytological specimens]

Area of Science:

• Oncology
• Molecular Biology
• Pulmonology

Background:

• Lung cancer treatment has advanced significantly, with targeted therapies showing efficacy in specific patient subsets.
• Targeted therapies are effective in a small fraction (<20%) of non-small cell lung cancer (NSCLC) patients.
• Somatic mutations in genes like EGFR and KRAS predict response to these targeted treatments.

Purpose of the Study:

• To discuss the challenges associated with molecular testing on cytological specimens for non-small cell lung cancer.
• To highlight the importance of molecular testing for guiding targeted therapy selection.
• To explore solutions for performing molecular diagnostics on non-histopathological samples.

Main Methods:

• Review of current literature on molecular testing in lung cancer.
• Analysis of the suitability of cytological specimens for molecular diagnostics.
• Discussion of technical issues and potential workarounds for molecular testing on cytology.

Main Results:

• Histopathological samples (biopsies, resections) are the standard for molecular testing.
• Cytological specimens present unique challenges for molecular testing.
• Accurate molecular profiling is essential for personalized lung cancer treatment.

Conclusions:

• Molecular testing on cytological specimens is a viable alternative when biopsies are unavailable.
• Addressing the technical challenges of cytological molecular testing is critical for expanding access to targeted therapies.
• Optimizing molecular diagnostics on cytology samples can improve treatment outcomes for non-small cell lung cancer patients.